Truist Securities Maintains Buy on Arcutis Biotherapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Gregory Fraser maintains a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) but lowers the price target from $45 to $40.
May 26, 2023 | 11:45 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Arcutis Biotherapeutics (ARQT) but lowers the price target from $45 to $40.
The news directly mentions Arcutis Biotherapeutics (ARQT) and the lowered price target by Truist Securities. While the Buy rating is maintained, the lowered price target may have a neutral impact on the stock price in the short term as it indicates a reduced upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100